|
|||||
|
|
A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation |
|
| Authors: | William D. Figg Maha H. Hussain Philip M. Arlen Jeanny B. Aragon-Ching Celestia S. Higano Gurkamal S. Chatta John J. Wright William L. Dahut |
| Affiliation: | a Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland b Molecular Pharmacology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland c Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland d Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland e Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland f Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland g Departments of Internal Medicine and Urology, University of Michigan Medical Center, Ann Arbor, and Department of Medical Oncology, Wayne State University/Barbara Ann Karmanos Cancer Institute, Detroit, Michigan h Department of Medicine, New York-Presbyterian Hospital/Columbia University Medical Center, New York, New York i Departments of Medicine and Urology, University of Washington, Seattle, Washington j Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania k Tulane Medical School, New Orleans, Louisiana |
| Abstract: | |
| Keywords: | prostatic neoplasms hormones thalidomide disease-free survival angiogenesis inhibitors |
| 本文献已被 ScienceDirect 等数据库收录！ | |